LFA-1 expression on CD4+ CCD45RO+ peripheral blood T-lymphocytes in RR MS:: effects induced by rIFNβ-1a

被引:5
作者
Avolio, C
Ruggieri, M
Cafforio, P
Giuliani, F
Silvestris, F
Dammacco, F
Livrea, P
Trojano, M
机构
[1] Univ Foggia, Chair Neurol, Foggia, Italy
[2] Univ Bari, Dept Neurol & Psychiat Sci, Bari, Italy
[3] Univ Bari, Dept Biomed Sci & Human Oncol, Bari, Italy
关键词
LFA-1; CD4(+) CD45RO(+); peripheral blood T-lymphocytes; interferon beta-1a; soluble ICAM-1; multiple sclerosis;
D O I
10.1016/S0022-510X(01)00506-8
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
We investigate the in vivo and in vitro effects of short-term treatment with recombinant Interferon beta-1a (rIFN beta -1a) on CD4(+)CD45RO(+) activated/memory peripheral blood T-lymphocytes (PBTLs) expressing Leukocyte Function Antigen-1 (LFA-1; CD11a/CD18) in relapsing-remitting (RR) Multiple Sclerosis (MS) patients. Blood samples were obtained from 10 RR MS patients before and after 2, 4 and 6 months of rIFN beta -1a (Avonex) treatment. For each sample, the percentage of CD4(+)CD45RO(+)CD11a(+) (CD11a(dim) and CD11a(bright)) T-cells was evaluated in in vivo PBTLs and in untreated or rIFN beta -1a (1000 U/ml) or recombinant soluble Intercellular Adhesion Molecule-1 (ICAM-1, the ligand for LFA-1) (400 ng/ml) treated cultured PBTLs by triple fluorescence flow-cytometry (FACS analysis). Soluble ICAM-1 (sICAM-1) serum levels were evaluated by ELISA. In vivo, the percentage of CD4(+) CD45RO(+), CD4(+) CD45RO(+)CD11a(+). CD4(+)CD45RO(+)CD11a(dim) PBTLs increased after 4 and 6 months of rIFN beta -1a treatment compared to pretreatment and 2 months of treatment (p < 0.05). The CD11a expression per se did not change during the time course. Soluble ICAM-1 (sICAM-1) serum levels also increased(p < 0.05) after 4 and 6 months of treatment. When T-cells, obtained from the blood of the same patients before and during in vivo treatment, were cultured either untreated or treated with rIFN beta -1a, they showed an increase in the percentage of CD4(+)CD45RO(+) T-cells expressing CD11a(bright) (p < 0.05). The addition of recombinant sICAM-1 to untreated cultures decreased the percentage of CD4(+)CD45RO(+) T-cells expressing CD11a. This last finding seems to support an indirect effect in vivo of rIFN<beta>-1a via sICAM-1 on this T-cell subset, since the ICAM-1 soluble form, induced in vivo in serum by rIFN beta -1a but lacking in in vitro conditions, keeps the percentage of CD11a(+) unchanged within CD4(+)CD45RO(+) T-cells and induces their expression of CD11a(dim), probably preventing T-cells from transmigrating. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:65 / 73
页数:9
相关论文
共 51 条
[21]  
KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444
[22]  
Li DKB, 1999, ANN NEUROL, V46, P197, DOI 10.1002/1531-8249(199908)46:2<197::AID-ANA9>3.0.CO
[23]  
2-P
[24]  
Lou JN, 1999, LAB INVEST, V79, P1015
[25]   Brain microvascular endothelial cells and leukocytes derived from patients with multiple sclerosis exhibit increased adhesion capacity [J].
Lou, JN ;
Chofflon, M ;
Juillard, C ;
Donati, Y ;
Mili, N ;
Siegrist, CA ;
Grau, GE .
NEUROREPORT, 1997, 8 (03) :629-633
[26]  
Lyons PD, 1998, GLIA, V22, P103, DOI 10.1002/(SICI)1098-1136(199802)22:2<103::AID-GLIA1>3.0.CO
[27]  
2-8
[28]   Immunoregulatory effects of interferon-beta and interacting cytokines on human vascular endothelial cells implications for multiple sclerosis and other autoimmune diseases [J].
Miller, A ;
Lanir, N ;
Shapiro, S ;
Revel, M ;
Honigman, S ;
Kinarty, A ;
Lahat, N .
JOURNAL OF NEUROIMMUNOLOGY, 1996, 64 (02) :151-161
[29]   VLA-4/CD49d downregulated on primed T lymphocytes during interferon-β therapy in multiple sclerosis [J].
Muraro, PA ;
Leist, T ;
Bielekova, B ;
McFarland, HF .
JOURNAL OF NEUROIMMUNOLOGY, 2000, 111 (1-2) :186-194
[30]   INTERFERON-BETA DECREASES T-CELL ACTIVATION AND INTERFERON-GAMMA PRODUCTION IN MULTIPLE-SCLEROSIS [J].
NORONHA, A ;
TOSCAS, A ;
JENSEN, MA .
JOURNAL OF NEUROIMMUNOLOGY, 1993, 46 (1-2) :145-154